IPO - MED EIBY Holding Co., Ltd

Form Type: F-1/A

Filing Date: 2025-01-17

Corporate Action: Ipo

Type: New

Accession Number: 000110465925004554

Filing Summary: This document is an amendment to the registration statement for an initial public offering (IPO) of 4,000,000 ordinary shares of MED EIBY Holding Co., Limited. The offering is being made on a firm commitment basis, with shares expected to be priced between $4.00 and $6.00. The company is incorporated in the Cayman Islands with its principal executive offices located in Shenzhen, China. The initial public offering is contingent upon final approval from Nasdaq for the listing of its shares under the symbol 'BSME'. The company notes significant risks associated with investment, including regulatory challenges related to its structure and potential delays in receiving necessary approvals from the Chinese government and securities authorities. The prospectus outlines the unique risks associated with the Variable Interest Entity (VIE) structure under which the company operates, as well as ongoing regulatory scrutiny faced by Chinese firms wishing to go public in the U.S.

Document Link: View Document

Form Type: F-1/A

Filing Date: 2024-12-23

Corporate Action: Ipo

Type: New

Accession Number: 000110465924130965

Filing Summary: MED EIBY Holding Co., Limited is filing an amendment to their Form F-1 registration statement to proceed with an initial public offering (IPO) of 4,000,000 ordinary shares at an expected price range between $4.00 to $6.00 per share. The application to list on the Nasdaq under the symbol 'BSME' is pending approval which is a prerequisite for the closing of this offering. This filing also states that they are an emerging growth company under U.S. laws, implying certain benefits in terms of regulatory compliance. The company confirms that there is no existing public market for its ordinary shares prior to this registration. It explains the corporate structure, highlighting that it operates through Variable Interest Entities (VIEs) due to Chinese regulations restricting foreign ownership in certain sectors. Investors are warned of unique risks related to this structure, including regulatory scrutiny in China that may alter or hinder their operations and investments. Moreover, the company discusses various regulations in China regarding overseas listings and emphasizes the risks associated with potential non-compliance with local laws, which could impact share value. They have submitted their application to the China Securities Regulatory Commission (CSRC) for compliance with Chinese regulations concerning overseas offerings, which is still pending. The summary indicates that the company has traditionally not paid dividends and intends to retain earnings for business development.

Document Link: View Document